Ocugen Seeks Shareholder Nod for Reverse Split Amid Pivotal Clinical Timeline

Ocugen seeks reverse stock split to maintain listing, with cash runway to key 2027 Phase 3 data for gene therapy OCU400. Recent clinical updates show progress.

Ocugen’s stock is a study in contrasts. While the share price has surged over 32% since the start of the year, it has also fallen nearly 14% in the past month, recently trading at 1.56 euros. This volatility underscores the biotech firm's precarious position as it balances promising clinical data against persistent financial pressures.

The company’s immediate challenge is maintaining its stock exchange listing. Management has submitted a revised proxy statement for its Annual Meeting on June 11, 2026, seeking shareholder approval for a reverse stock split. The board is proposing a consolidation within a range of 1-for-2 to 1-for-8, a move designed to meet minimum share price requirements. This follows a disappointing first quarter where Ocugen reported a loss of $0.06 per share and revenues fell into negative territory, missing analyst expectations for nearly $1 million in sales.

Financing its ambitious pipeline remains a core focus. Ocugen has recently bolstered its balance sheet through two key transactions. A direct stock offering in January 2026 raised $22.5 million, followed by the exercise of warrants that brought in an additional $15 million. Company leadership now estimates its cash reserves are sufficient to fund operations into the first quarter of 2027. This runway is strategically aligned with a major upcoming catalyst.

That catalyst is the release of topline data from the pivotal Phase 3 liMeliGhT trial for its gene therapy candidate, OCU400. The company has completed enrollment, randomizing 140 patients for this critical study. Results are anticipated in early 2027, a date that represents the next significant milestone for the company's long-term valuation.

Concurrently, Ocugen is reporting encouraging progress from its other programs. New data from the Phase 2 study for OCU410 showed its optimal dose reduced lesion growth by a statistically significant 31% (p<0.05). More than half of treated patients experienced a lesion reduction of at least 30%, and 27% of patients showed preservation of the ellipsoid zone, a key indicator of photoreceptor health. Dosing has also been completed for 63 participants in the separate GARDian3 study.

Despite a recent one-day jump of over 11% to 1.61 euros on the back of this clinical news, the stock remains approximately 26% below its 52-week high of 2.17 euros. The path forward is clear: shareholder approval for the reverse split would address near-term compliance concerns, but the true inflection point for Ocugen’s equity hinges on the clinical readouts slated for 2027.